Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Silo Pharma, Inc. (SILO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1700-0.0030 (-1.73%)
At close: 03:58PM EST
Advertisement

Silo Pharma, Inc.

560 Sylvan Avenue
Suite 3160
Englewood Cliffs, NJ 07632
United States
718 400 9031
https://silopharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees1

Key Executives

NameTitlePayExercisedYear Born
Mr. Eric WeisblumChairman, Pres, Chief Compliance Officer, CEO & CFO115kN/A1970
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company focuses on merging traditional therapeutics with psychedelic research to address conditions, such as depression, post-traumatic stress disorder, Parkinson's, and other rare neurological disorders. It has a scientific research agreement with the University of Maryland. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Englewood Cliffs, New Jersey.

Corporate Governance

Silo Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement